PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Seductive early trial results showed massive reductions in LDL cholesterol among patients who took PCSK9 inhibitors—the new injectable cholesterol-lowering medications—including those already taking high-intensity statin therapy. Now that they are on the market, physicians are coming to terms with how to best use the costly drugs in selective patients.

Read more at tctmd